Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival

British Journal of Haematology

Volumn 130, Issue 4, 2005, Pages 542-548

  Lovell, Richard ^a,b   Dunn, Janet A ^a   Begum, Gulnaz ^a   Barth, Nicola J ^a   Plant, Tim ^a   Moss, Paul A ^a   Drayson, Mark T ^a   Pratt, Guy ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Multiple myeloma; Prognostic factors

Indexed keywords

CARMUSTINE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISOLONE; SYNDECAN 1; MEMBRANE PROTEIN; PROTEOGLYCAN; SDC1 PROTEIN, HUMAN; SYNDECAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SAMPLE; BLOOD; CHI SQUARE DISTRIBUTION; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; PROTEOGLYCANS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SYNDECAN-1; SYNDECANS; TUMOR MARKERS, BIOLOGICAL;

EID: 24944526709     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05647.x     Document Type: Article

References (33)

1. Andersen N.F. Standal T. Nielsen J.L. Heickendorff L. Borset M. Sorensen F.B. Abildgaard N. ( 2005) Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. British Journal of Haematology, 128, 210 217.
2. Aref S. Goda T. El-Sherbiny M. ( 2003) Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors. Hematology, 8, 221 228.
3. Attal M. Harousseau J.L. Facon T. Guilhot F. Doyen C. Fuzibet J.G. Monconduit M. Hulin C. Caillot D. Bouabdallah R. Voillat L. Sotto J.J. Grosbois B. Bataille R. ( 2003) Single versus double autologous stem cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 2495 2502.
4. Blade J. Lopez-Guillermo A. Bosch F. Cervantes F. Reverter J.C. Montserrat E. Rozman C. ( 1994) Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. British Journal of Haematology, 88, 117 121.
5. Boccadoro M. Marmont F. Tribalto M. Fossati G. Redoglia V. Battaglio S. Massaia M. Gallamini A. Comotti B. Barbui T. ( 1989) Early responder myeloma: kinetic studies identify a patient subgroup characterised by very poor prognosis. Journal of Clinical Oncology, 7, 119 125.
6. Carey D.J. ( 1997) Syndecans: multifunctional cell-surface co-receptors. Journal of Biochemistry, 327, 1 16.
7. Chen D. Adenekan B. Chen L. Vaughan E.D. Gerald W. Feng Z. Knudsen B.S. ( 2004) Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology, 63, 402 407.
8. Cox D.R. ( 1972) Regression models and life tables. Journal of the Royal Statistical Society Series B, 34, 187 220.
9. Cuzick J. Cooper E.H. MacLennan I.C.M. ( 1985) The prognostic value of serum Beta-2 microglobulin compared with other presentation features in myelomatosis - (a report to the medical-research-councils working party on leukemia in adults). British Journal of Cancer, 52, 1 6.
10. Davies E.J. Blackhall F.H. Shanks J.H. David G. McGown A.T. Swindell R. Slade R.J. Martin-Hirsch P. Gallagher J.T. Jayson G.C. ( 2004) Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clinical Cancer Research, 10, 5178 5186.
11. Derksen P.W. Keehen R.M. Evers L.M. van Oers M.H. Spaargaren M. Pals S.T. ( 2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood, 99, 1405 1410.
12. Dhodapkar M.V. Kelly T. Theus A. Athota A.B. Barlogie B. Sanderson R.D. ( 1997) Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. British Journal of Haematology, 99, 368 371.
13. Dhodapkar M.V. Abe E. Theus A. Lacy M. Langford J.K. Barlogie B. Sanderson R.D. ( 1998) Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth and bone cell differentiation. Blood, 91, 2679 2688.
14. Dunn J.A. Drayson M.T. Begum G. Barth N.J. MacLennan I.C.M. ( 2005) The search for a new and improved staging system for non-intensive therapy: the UK Medical Research Council's experience. The Hematology Journal, 90, abstract 309.
15. Durie B.G. Salmon S.E. ( 1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842 854.
16. Durie B.G. Jacobson J. Barlogie B. Crowley J. ( 2004) Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. Journal of Clinical Oncology, 22, 1857 1863.
17. Greipp P.R. San Miguel J.F. Durie B.G. Loiseau H.A. Fonseca R. Jacobson J.L. Rasmussen E. Crowley J.J. ( 2003) A new international staging system (ISS) for multiple myeloma (MM) from the International Myeloma Working Group. Blood, 102 ( Suppl. 1 664.
18. Janosi J. Sebestyen A. Mikala G. Nemeth J. Kiss Z. Valyi-Nagy I. ( 2004) Soluble syndecan-1 levels in different plasma cell dyscrasias and in different stages of multiple myeloma. Haematologica, 89, 370 371.
19. Kaplan E.L. Meier P. ( 1958) Non parametric estimation from incomplete observations. Journal of Statistical Association, 53, 457 481.
20. Kumar S. Blood E. Oken M.M. Greipp P.R. ( 2004) Prognostic value of syndecan-1 in multiple myeloma and its relationship with other prognostic factors. Blood, 104 ( Suppl. 1 2402.
21. Kyrtsonis M.C. Vassilakopoulos T.P. Siakantaris M.P. Kokoris S.I. Gribabis D.A. Dimopoulou M.N. Angelopoulou M.K. Pangalis G.A. ( 2004) Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. European Journal of Haematology, 72, 252 258.
22. Langford J.K. Yang Y. Kieber-Emmons T. Sanderson R.D. ( 2005) Identification of an invasion regulatory domain within the core protein of syndecan-1. Journal of Biological Chemistry, 280, 3467 3473.
23. Leivonen M. Lundin J. Nordling S. von Boguslawski K. Haglund C. ( 2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology, 67, 11 18.
24. Mali M. Andtfolk H. Miettinen H.M. Jalkanen M. ( 1994) Suppression of tumor cell growth by syndecan-1 ectodomain. Journal of Biological Chemistry, 269, 27 795 27 798.
25. Marmont F. Levis A. Falda M. Rosegotti L. ( 1991) Lack of correlation between objective response and death rate in mutliple myeloma patients treated with oral melphalan and prednisone. Annals of Oncology, 2, 191 195.
26. Olujohungbe A.B. Dunn J.A. Drayson M.T. MacLennan I.C.M. ( 1996) Prednisolone added to the ABCM as treatment for multiple myeloma increases serological responses but not overall survival or the number of stable clinical responses. British Journal of Haematology, 93 ( Suppl. 1 296.
27. Peto R. Pike M. Armitage P. ( 1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. British Journal of Cancer, 35, 1 39.
28. Sanderson R.D. Borset M. ( 2002) Syndecan-1 in B lymphoid malignancies. Annals of Hematology, 81, 125 135.
29. Schaar C.G. Kluin-Nelemans J.C. le Cessie S. Franck P.F. te Marvelde M.C. Wijermans P.W. ( 2004) Early response to therapy and survival in multiple myeloma. British Journal of Haematology, 125, 162 166.
30. Seidel C. Borset M. Hjertner O. Cao D. Abildgaard N. Hjorth-Hansen H. Sanderson R.D. Waage A. Sundan A. ( 2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood, 95, 388 392.
31. Shah L. Walter K.L. Borczuk A.C. Kawut S.M. Sonett J.R. Gorenstein L.A. Ginsburg M.E. Steinglass K.M. Powell C.A. ( 2004) Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer, 101, 1632 1638.
32. Standal T. Seidel C. Hjertner O. Plesner T. Sanderson R.D. Waage A. Borset M. Sundan A. ( 2002) Osteoprotegerin is bound, internalised and degraded by multiple myeloma cells. Blood, 100, 3002 3007.
33. Yang Y. Yaccoby S. Wei L. Langford K. Pumphrey C.Y. Theus A. Epstein J. Sanderson R.D. ( 2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 100, 610 617.